Suppr超能文献

2020 年 5 月至 6 月印度全国血清学调查的 SARS-CoV-2 感染流行率。

Prevalence of SARS-CoV-2 infection in India: Findings from the national serosurvey, May-June 2020.

机构信息

ICMR-National Institute of Epidemiology, Chennai, Tamil Nadu, India.

ICMR School of Public Health, Chennai, Tamil Nadu, India.

出版信息

Indian J Med Res. 2020;152(1 & 2):48-60. doi: 10.4103/ijmr.IJMR_3290_20.

Abstract

BACKGROUND & OBJECTIVES: Population-based seroepidemiological studies measure the extent of SARS-CoV-2 infection in a country. We report the findings of the first round of a national serosurvey, conducted to estimate the seroprevalence of SARS-CoV-2 infection among adult population of India.

METHODS

From May 11 to June 4, 2020, a randomly sampled, community-based survey was conducted in 700 villages/wards, selected from the 70 districts of the 21 States of India, categorized into four strata based on the incidence of reported COVID-19 cases. Four hundred adults per district were enrolled from 10 clusters with one adult per household. Serum samples were tested for IgG antibodies using COVID Kavach ELISA kit. All positive serum samples were re-tested using Euroimmun SARS-CoV-2 ELISA. Adjusting for survey design and serial test performance, weighted seroprevalence, number of infections, infection to case ratio (ICR) and infection fatality ratio (IFR) were calculated. Logistic regression was used to determine the factors associated with IgG positivity.

RESULTS

Total of 30,283 households were visited and 28,000 individuals were enrolled. Population-weighted seroprevalence after adjusting for test performance was 0.73 per cent [95% confidence interval (CI): 0.34-1.13]. Males, living in urban slums and occupation with high risk of exposure to potentially infected persons were associated with seropositivity. A cumulative 6,468,388 adult infections (95% CI: 3,829,029-11,199,423) were estimated in India by the early May. The overall ICR was between 81.6 (95% CI: 48.3-141.4) and 130.1 (95% CI: 77.0-225.2) with May 11 and May 3, 2020 as plausible reference points for reported cases. The IFR in the surveyed districts from high stratum, where death reporting was more robust, was 11.72 (95% CI: 7.21-19.19) to 15.04 (9.26-24.62) per 10,000 adults, using May 24 and June 1, 2020 as plausible reference points for reported deaths.

INTERPRETATION & CONCLUSIONS: Seroprevalence of SARS-CoV-2 was low among the adult population in India around the beginning of May 2020. Further national and local serosurveys are recommended to better inform the public health strategy for containment and mitigation of the epidemic in various parts of the country.

摘要

背景与目的

基于人群的血清流行病学研究衡量了一个国家的 SARS-CoV-2 感染程度。我们报告了第一轮全国血清学调查的结果,该调查旨在估计印度成年人口中 SARS-CoV-2 感染的血清流行率。

方法

2020 年 5 月 11 日至 6 月 4 日,在印度 21 个邦的 70 个区中随机选择的 700 个村庄/病房进行了一项基于社区的调查,根据报告的 COVID-19 病例发生率将这些区分为四个层次。每个区从 10 个集群中招募 400 名成年人,每个家庭有 1 名成年人。使用 COVID Kavach ELISA 试剂盒检测血清 IgG 抗体。使用 Euroimmun SARS-CoV-2 ELISA 对所有阳性血清样本进行重新检测。在调整了调查设计和连续测试性能后,计算了加权血清流行率、感染人数、感染病例比 (ICR) 和感染病死率 (IFR)。使用逻辑回归确定与 IgG 阳性相关的因素。

结果

共访问了 30283 户家庭,招募了 28000 人。在调整测试性能后,人群加权血清流行率为 0.73%[95%置信区间 (CI):0.34-1.13]。男性、居住在城市贫民窟和从事可能接触潜在感染人员的高风险职业与血清阳性相关。到 5 月初,印度估计有 646.838 名成年人感染(95%CI:382.9029-1119.9423)。总体 ICR 介于 81.6(95%CI:48.3-141.4)和 130.1(95%CI:77.0-225.2)之间,5 月 11 日和 5 月 3 日是报告病例的合理参考点。在死亡报告更可靠的高分层调查区,使用 5 月 24 日和 6 月 1 日作为报告死亡的合理参考点,死亡率为每 10000 名成年人 11.72(95%CI:7.21-19.19)至 15.04(9.26-24.62)。

解释与结论

2020 年 5 月初,印度成年人口中 SARS-CoV-2 的血清流行率较低。建议进一步进行全国和地方血清学调查,以便更好地为全国各地区的疫情防控和缓解策略提供信息。

相似文献

1
Prevalence of SARS-CoV-2 infection in India: Findings from the national serosurvey, May-June 2020.
Indian J Med Res. 2020;152(1 & 2):48-60. doi: 10.4103/ijmr.IJMR_3290_20.
2
SARS-CoV-2 antibody seroprevalence in India, August-September, 2020: findings from the second nationwide household serosurvey.
Lancet Glob Health. 2021 Mar;9(3):e257-e266. doi: 10.1016/S2214-109X(20)30544-1. Epub 2021 Jan 27.
3
Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study.
Lancet. 2020 Aug 1;396(10247):313-319. doi: 10.1016/S0140-6736(20)31304-0. Epub 2020 Jun 11.
5
Development of indigenous IgG ELISA for the detection of anti-SARS-CoV-2 IgG.
Indian J Med Res. 2020 May;151(5):444-449. doi: 10.4103/ijmr.IJMR_2232_20.
6
Seroprevalence of SARS-CoV-2 specific IgG antibodies in District Srinagar, northern India - A cross-sectional study.
PLoS One. 2020 Nov 11;15(11):e0239303. doi: 10.1371/journal.pone.0239303. eCollection 2020.
8
Antibody tests for identification of current and past infection with SARS-CoV-2.
Cochrane Database Syst Rev. 2020 Jun 25;6(6):CD013652. doi: 10.1002/14651858.CD013652.
9
10
SARS-CoV-2 antibody prevalence in Brazil: results from two successive nationwide serological household surveys.
Lancet Glob Health. 2020 Nov;8(11):e1390-e1398. doi: 10.1016/S2214-109X(20)30387-9. Epub 2020 Sep 23.

引用本文的文献

1
Modelling and analysis of COVID-19 epidemic in India.
J Saf Sci Resil. 2020 Dec;1(2):135-140. doi: 10.1016/j.jnlssr.2020.11.005. Epub 2020 Nov 28.
2
Antibody Responses to SARS-CoV-2 among Health Care Workers in North-Eastern Tanzania.
East Afr Health Res J. 2024;8(3):305-314. doi: 10.24248/eahrj.v8i3.799. Epub 2025 Jan 30.
3
6
Serosurveillance of COVID-19 amongst health care workers in a teaching institution - A prospective cohort study in Puducherry district.
J Family Med Prim Care. 2024 May;13(5):1917-1921. doi: 10.4103/jfmpc.jfmpc_1488_23. Epub 2024 May 24.
8
Vaccination coverage against COVID-19 among rural population in Haryana, India: A cross-sectional study.
PLoS One. 2024 Mar 8;19(3):e0299564. doi: 10.1371/journal.pone.0299564. eCollection 2024.
10

本文引用的文献

1
COVID-19 antibody seroprevalence in Santa Clara County, California.
Int J Epidemiol. 2021 May 17;50(2):410-419. doi: 10.1093/ije/dyab010.
2
Adjusting Coronavirus Prevalence Estimates for Laboratory Test Kit Error.
Am J Epidemiol. 2021 Jan 4;190(1):109-115. doi: 10.1093/aje/kwaa174.
3
Serology-informed estimates of SARS-CoV-2 infection fatality risk in Geneva, Switzerland.
Lancet Infect Dis. 2021 Apr;21(4):e69-e70. doi: 10.1016/S1473-3099(20)30584-3. Epub 2020 Jul 14.
4
Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study.
Lancet. 2020 Aug 22;396(10250):535-544. doi: 10.1016/S0140-6736(20)31483-5. Epub 2020 Jul 6.
5
First confirmed case of COVID-19 infection in India: A case report.
Indian J Med Res. 2020 May;151(5):490-492. doi: 10.4103/ijmr.IJMR_2131_20.
6
Development of indigenous IgG ELISA for the detection of anti-SARS-CoV-2 IgG.
Indian J Med Res. 2020 May;151(5):444-449. doi: 10.4103/ijmr.IJMR_2232_20.
9
How deadly is the coronavirus? Scientists are close to an answer.
Nature. 2020 Jun;582(7813):467-468. doi: 10.1038/d41586-020-01738-2.
10
Seroepidemiologic Study Designs for Determining SARS-COV-2 Transmission and Immunity.
Emerg Infect Dis. 2020 Sep;26(9):1978-1986. doi: 10.3201/eid2609.201840. Epub 2020 Jun 16.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验